ArticleBMC musculoskeletal disorders2025
miR-29a-3p serves as a potential biomarker for diagnosing spinal tuberculosis: a comprehensive analysis integrating clinical data and molecular markers.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSpinal tuberculosis (STB), the most common bone and joint tuberculosis, often causes spinal deformity and impairs quality of life. While microRNAs (miRNAs) regulate various disease pathogenesis, their expression and function in STB remain poorly understood.
methods100 STB patients (observation group) from Ningxia Medical University Affiliated Hospital (Jan 2021-Dec 2024) and 100 healthy controls were enrolled. miRNA high-throughput sequencing of 3 samples per group identified differentially expressed miRNAs, validated via known STB signaling pathways. Real-time fluorescence quantitative reverse transcription PCR(RT-qPCR) quantified peripheral blood miR-29a-3p in all participants. Clinical data were collected. Independent samples t-tests, linear regression, Spearman correlation, and receiver operating characteristic(ROC) curves analyzed miR-29a-3p's expression differences, associations with clinical parameters, and diagnostic performance (alone or combined with conventional indicators).
resultsPeripheral blood miR-29a-3p was significantly lower in STB patients (AUC = 0.864). It negatively correlated with erythrocyte sedimentation rate(ESR) and C-reactive protein(CRP) but not with white blood cell count, disease duration, or neutrophil percentage. Combining miR-29a-3p with bacteriological testing, T-cell spot test(T-SPOT), and imaging significantly improved diagnostic performance.
conclusionmiR-29a-3p shows distinct low expression in STB patients' peripheral blood, associated with inflammation activity and conventional diagnostic indicators, making it a promising auxiliary biomarker. Critically, integrating miR-29a-3p into combined detection strategies enhances and optimizes current STB diagnostic frameworks, addressing unmet clinical needs for more accurate and efficient diagnosis, thus holding substantial value for improving STB management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.